Goodnow, C. C., Crosbie, J., A<strong>de</strong>lstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Lob<strong>la</strong>y, R. H., Raphael, K. et al. (1988). Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334, 676-82. Gu, M., Wang, W., Song, W. K., Cooper, D. N. and Kaufman, S. J. (1994). Selective modu<strong>la</strong>tion of the interaction of alpha 7 beta 1 integrin with fibronectin and <strong>la</strong>minin by L-14 lectin during skeletal muscle differentiation. J Cell Sci 107 (Pt 1), 175-81. Guerrini, M., Agulles, T., Bisio, A., Hricovini, M., Lay, L., Naggi, A., Poletti, L., Sturiale, L., Torri, G. and Casu, B. (2002). Minimal heparin/heparan sulfate sequences for binding to fibrob<strong>la</strong>st growth factor-1. Biochem Biophys Res Commun 292, 222-30. Guo, B., Kato, R. M., Garcia-Lloret, M., Wahl, M. I. and Rawlings, D. J. (2000). Engagement of the human pre-B cell receptor generates a lipid raft-<strong>de</strong>pen<strong>de</strong>nt calcium signaling complex. Immunity 13, 243-53. Gupta-Bansal, R., Fre<strong>de</strong>rickson, R. C. and Brun<strong>de</strong>n, K. R. (1995). Proteoglycanmediated inhibition of A beta proteolysis. A potential cause of senile p<strong>la</strong>que accumu<strong>la</strong>tion. J Biol Chem 270, 18666-71. Habas, R., Dawid, I. B. and He, X. (2003). Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastru<strong>la</strong>tion. Genes Dev 17, 295-309. Hacker, H., Re<strong>de</strong>cke, V., B<strong>la</strong>goev, B., Kratchmarova, I., Hsu, L. C., Wang, G. G., Kamps, M. P., Raz, E., Wagner, H., Hacker, G. et al. (2006). Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204-7. Hadari, Y. R., Arbel-Goren, R., Levy, Y., Amsterdam, A., Alon, R., Zakut, R. and Zick, Y. (2000). Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci 113 (Pt 13), 2385-97. Haltiwanger, R. S. and Lowe, J. B. (2004). Role of glycosy<strong>la</strong>tion in <strong>de</strong>velopment. Annu Rev Biochem 73, 491-537. Han, H., Tanigaki, K., Yamamoto, N., Kuroda, K., Yoshimoto, M., Nakahata, T., Ikuta, K. and Honjo, T. (2002). Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage <strong>de</strong>cision. Int Immunol 14, 637-45. Harduin-Lepers, A., Vallejo-Ruiz, V., Krzewinski-Recchi, M. A., Samyn-Petit, B., Julien, S. and De<strong>la</strong>nnoy, P. (2001). The human sialyltransferase family. Biochimie 83, 727-37. Hardy, R. R. (2006). B-1 B cell <strong>de</strong>velopment. J Immunol 177, 2749-54. Hardy, R. R., Carmack, C. E., Shinton, S. A., Kemp, J. D. and Hayakawa, K. (1991). Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 173, 1213-25. Harris, R. J. and Spellman, M. W. (1993). O-linked fucose and other post-trans<strong>la</strong>tional modifications unique to EGF modules. Glycobiology 3, 219-24. Hartley, S. B., Cooke, M. P., Fulcher, D. A., Harris, A. W., Cory, S., Basten, A. and Goodnow, C. C. (1993). Elimination of self-reactive B lymphocytes proceeds in two stages: arrested <strong>de</strong>velopment and cell <strong>de</strong>ath. Cell 72, 325-35. Hasan, M., Polic, B., Bralic, M., Jonjic, S. and Rajewsky, K. (2002). Incomplete block of B cell <strong>de</strong>velopment and immunoglobulin production in mice carrying the muMT mutation on the BALB/c background. Eur J Immunol 32, 3463-71. Hashimoto, S., Iwamatsu, A., Ishiai, M., Okawa, K., Yamadori, T., Matsushita, M., Baba, Y., Kishimoto, T., Kurosaki, T. and Tsukada, S. (1999). I<strong>de</strong>ntification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling. Blood 94, 2357-64. 160
Hauke, G., Epplen, J. T., Chluba, J., Hollmann, A. and Peter, H. H. (1988). IgD/<strong>la</strong>mbda p<strong>la</strong>smocytoma with immunoglobulin kappa light-chain genes in the germ-line configuration. J Clin Immunol 8, 407-13. Hecht, A. and Kemler, R. (2000). Curbing the nuclear activities of beta-catenin. Control over Wnt target gene expression. EMBO Rep 1, 24-8. Hertz, M. and Nemazee, D. (1997). BCR ligation induces receptor editing in IgM+IgD- bone marrow B cells in vitro. Immunity 6, 429-36. Hibbs, M. L., Tarlinton, D. M., Armes, J., Grail, D., Hodgson, G., Maglitto, R., Stacker, S. A. and Dunn, A. R. (1995). Multiple <strong>de</strong>fects in the immune system of Lyn-<strong>de</strong>ficient mice, culminating in autoimmune disease. Cell 83, 301-11. Hieter, P. A., Korsmeyer, S. J., Waldmann, T. A. and Le<strong>de</strong>r, P. (1981). Human immunoglobulin kappa light-chain genes are <strong>de</strong>leted or rearranged in <strong>la</strong>mbda-producing B cells. Nature 290, 368-72. Hippen, K. L., Buhl, A. M., D'Ambrosio, D., Nakamura, K., Persin, C. and Cambier, J. C. (1997). Fc gammaRIIB1 inhibition of BCR-mediated phosphoinositi<strong>de</strong> hydrolysis and Ca2+ mobilization is integrated by CD19 <strong>de</strong>phosphory<strong>la</strong>tion. Immunity 7, 49-58. Hodoniczky, J., Zheng, Y. Z. and James, D. C. (2005). Control of recombinant monoclonal antibody effector functions by Fc N-glycan remo<strong>de</strong>ling in vitro. Biotechnol Prog 21, 1644-52. Hoffmann, A., Kerr, S., Jellusova, J., Zhang, J., Weisel, F., Wellmann, U., Winkler, T. H., Kneitz, B., Crocker, P. R. and Nitschke, L. (2007). Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell popu<strong>la</strong>tion. Nat Immunol 8, 695-704. Hombach, J., Leclercq, L., Radbruch, A., Rajewsky, K. and Reth, M. (1988). A novel 34-kd protein co-iso<strong>la</strong>ted with the IgM molecule in surface IgM-expressing cells. Embo J 7, 3451-6. Hombach, J., Lottspeich, F. and Reth, M. (1990). I<strong>de</strong>ntification of the genes encoding the IgM-alpha and Ig-beta components of the IgM antigen receptor complex by amino-terminal sequencing. Eur J Immunol 20, 2795-9. Honjo, Y., Nangia-Makker, P., Inohara, H. and Raz, A. (2001). Down-regu<strong>la</strong>tion of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7, 661-8. Horikawa, K., Martin, S. W., Pogue, S. L., Silver, K., Peng, K., Takatsu, K. and Goodnow, C. C. (2007). Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J Exp Med 204, 759-69. Hoyer, K. K., Pang, M., Gui, D., Shintaku, I. P., Kuwabara, I., Liu, F. T., Said, J. W., Baum, L. G. and Teitell, M. A. (2004). An anti-apoptotic role for galectin-3 in diffuse <strong>la</strong>rge Bcell lymphomas. Am J Pathol 164, 893-902. Hozumi, K., Negishi, N., Suzuki, D., Abe, N., Sotomaru, Y., Tamaoki, N., Mailhos, C., Ish-Horowicz, D., Habu, S. and Owen, M. J. (2004). Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat Immunol 5, 638-44. Huber, C., Huber, E., Lautner-Rieske, A., Schable, K. F. and Zachau, H. G. (1993). The human immunoglobulin kappa locus. Characterization of the partially duplicated L regions. Eur J Immunol 23, 2860-7. Huelsken, J. and Birchmeier, W. (2001). New aspects of Wnt signaling pathways in higher vertebrates. Curr Opin Genet Dev 11, 547-53. Hughes, R. C. (1999). Secretion of the galectin family of mammalian carbohydratebinding proteins. Biochim Biophys Acta 1473, 172-85. 161
- Page 1:
UNIVERSITE DE LIMOGES Ecole doctora
- Page 4 and 5:
de m’avoir donnée le goût pour
- Page 6 and 7:
KO : « knock-out » : délétion d
- Page 8 and 9:
Figure 27 : Les trois types de N-gl
- Page 10 and 11:
5.2.2. Les galectines, les voies No
- Page 13 and 14:
Afin d’assurer la défense de l
- Page 15:
conduire les cellules B au long de
- Page 19 and 20:
Les immunoglobulines sont des hét
- Page 21 and 22:
antigènes et dans la transduction
- Page 23 and 24:
1.2.2 Le Locus Igλ Les gènes de c
- Page 25 and 26:
empêcher des recombinaisons illég
- Page 27 and 28:
de l’ADN est réalisée par les p
- Page 29 and 30:
Figure 8 : Les nucléotides N et P.
- Page 31 and 32:
séquences Ig (Goodhardt et al., 19
- Page 33 and 34:
B, le nombre de cellules exprimant
- Page 35 and 36:
Des promoteurs ont également été
- Page 37 and 38:
maturation : aux stades précoces,
- Page 39 and 40:
jusqu’à Cδ, ne supprime pas pou
- Page 41 and 42:
3.1 La phase indépendante des anti
- Page 43 and 44:
Novobrantseva et al., 1999) et que
- Page 45 and 46:
Figure 14 : Bilan des blocages part
- Page 47 and 48:
Dendritic Cells »). Elles devienne
- Page 49 and 50:
sécrétrices est controversée. De
- Page 51 and 52:
et al., 2000; Chumley et al., 2000;
- Page 53 and 54:
La commutation isotypique, permetta
- Page 55 and 56:
L’action des cytokines semble s
- Page 57 and 58:
l’hypermutation (Muramatsu et al.
- Page 59 and 60:
IV. L’activation des lymphocytes
- Page 61 and 62:
La translocation du BCR après pont
- Page 63 and 64:
protéines. La protéine ZAP-70 ét
- Page 65 and 66:
comme NF-κB (Krappmann et al., 200
- Page 67 and 68:
démontré que CD22 était continue
- Page 69 and 70:
Figure 24 : Comparaison des région
- Page 71 and 72:
Au cours du développement B, le pr
- Page 73 and 74:
membranaire s’avère possible exp
- Page 75 and 76:
IgM/IgD (Brink et al., 1992; Spanop
- Page 77 and 78:
V. « Glycannes et glycoconjugués
- Page 79 and 80:
Groupe d'enzymes Sialyltransférase
- Page 81 and 82:
L’édification d’une structure
- Page 83 and 84:
5.1.2. La O-glycosylation des prot
- Page 85 and 86:
• la O-glucosylation qui a lieu s
- Page 87 and 88:
Les protéoglycannes peuvent varier
- Page 89 and 90:
o L’Héparane Sulfate (HS) et l
- Page 91 and 92:
C’est le premier hexosamine greff
- Page 93 and 94:
égion constante. L’analyse des d
- Page 95 and 96:
pathologies pour lesquelles l’ars
- Page 97 and 98:
intégrines VLA-4, VLA-5 et α4β7,
- Page 99 and 100:
thymocytes double négatifs CD4- CD
- Page 101 and 102:
délétion conditionnelle des gène
- Page 103 and 104:
Dans la MEC, les protéoglycannes f
- Page 105 and 106:
endothéliale, de façon à permett
- Page 107 and 108:
Résultats - Discussion 107
- Page 109 and 110: Première partie : les BCR modifié
- Page 111 and 112: Article 1 “Premature expression o
- Page 113 and 114: Article 2 “B cells carying an IgE
- Page 115 and 116: Demande de dépôt de brevet Etabli
- Page 117 and 118: mécanismes relèvent les différen
- Page 119 and 120: Etablissement et caractérisation d
- Page 121 and 122: AUSUBEL, 2000, Wiley and son Inc, L
- Page 123 and 124: 4) Dosage du taux des IgG1 sérique
- Page 125 and 126: - distribution d’un antisérum an
- Page 127 and 128: périphériques expriment pour envi
- Page 129 and 130: C. CONCLUSION Ce travail a reposé
- Page 131 and 132: Deuxième partie : les glycosaminog
- Page 133 and 134: Article 3 “Modulation of glycotra
- Page 135 and 136: Perspectives 135
- Page 137 and 138: L’état des réflexions sur les i
- Page 139 and 140: équipes de Tsubata et Goodnow avai
- Page 141 and 142: L’ouverture d’un nouveau champ
- Page 143 and 144: « Lymphomagenèse » dirigé par l
- Page 145 and 146: Annexes 145
- Page 147 and 148: Article 4 “RNA surveillance down-
- Page 149 and 150: Article 5 “Light chain inclusion
- Page 151 and 152: Références Bibliographiques 151
- Page 153 and 154: Abney, E. R., Cooper, M. D., Kearne
- Page 155 and 156: Brink, R., Goodnow, C. C., Crosbie,
- Page 157 and 158: Cogne, M., Lansford, R., Bottaro, A
- Page 159: Franke, T. F., Kaplan, D. R., Cantl
- Page 163 and 164: Kao, Y. H., Lee, G. F., Wang, Y., S
- Page 165 and 166: Lieberson, R., Giannini, S. L., Bir
- Page 167 and 168: Meek, K. D., Hasemann, C. A. and Ca
- Page 169 and 170: Oberdoerffer, P., Novobrantseva, T.
- Page 171 and 172: Poellinger, L., Yoza, B. K. and Roe
- Page 173 and 174: Sato, M., Adachi, T. and Tsubata, T
- Page 175 and 176: Functional immunoglobulin transgene
- Page 177 and 178: Vilen, B. J., Famiglietti, S. J., C
- Page 179 and 180: Zarrin, A. A., Tian, M., Wang, J.,